MedinCell S.A. (FRA:MEB)

Market Cap	781.44M +14.4%
Revenue (ttm)	24.28M -12.4%
Net Income	-31.29M
EPS	-0.94
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	21.80
Previous Close	21.16
Day's Range	21.44 - 21.86
52-Week Range	19.01 - 37.82
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 8, 2026

About MedinCell

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of po...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MEB

Financial Performance

In fiscal year 2026, MedinCell's revenue was 24.28 million, a decrease of -12.44% compared to the previous year's 27.73 million. Losses were -31.29 million, 69.7% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 18, 2026

Data Sources Report a data error